Abiopharma

🔍 Moore David Scott (Executive)

Company: Corvus Pharmaceuticals, Inc. (CRVS)

Report Date: 2026-06-11

Detailed Transactions and Holdings:

• Acquired 21,700 shares of Common Stock at $11.5316 per share (Direct)
  Date: 2026-06-11 | Code: P | equity_swap_involved: 0 | shares_owned_after: 21,700.00 | transaction_form_type: 4
• Acquired 15,000 shares of Stock Option (Right to Buy) at $11.6 per share (Derivative)
  Date: 2026-06-11 | Code: A | Expires: 2036-06-11 | equity_swap_involved: 0 | shares_owned_after: 15,000.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.